164 related articles for article (PubMed ID: 18611989)
1. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.
van den Elskamp IJ; Lembcke J; Dattola V; Beckmann K; Pohl C; Hong W; Sandbrink R; Wagner K; Knol DL; Uitdehaag B; Barkhof F
Mult Scler; 2008 Jul; 14(6):764-9. PubMed ID: 18611989
[TBL] [Abstract][Full Text] [Related]
2. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.
Bagnato F; Jeffries N; Richert ND; Stone RD; Ohayon JM; McFarland HF; Frank JA
Brain; 2003 Aug; 126(Pt 8):1782-9. PubMed ID: 12821527
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP
Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
[TBL] [Abstract][Full Text] [Related]
5. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
7. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
8. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
9. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Zhao Y; Traboulsee A; Petkau AJ; Li D
Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
[TBL] [Abstract][Full Text] [Related]
10. [Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results].
Siger-Zajdel M; Lewańska M; Zaleski K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z; Selmaj K
Neurol Neurochir Pol; 2003; 37(6):1185-97. PubMed ID: 15174232
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis.
Morgen K; Crawford AL; Stone RD; Martin R; Richert ND; Frank JA; McFarland HF
Mult Scler; 2005 Apr; 11(2):146-8. PubMed ID: 15794386
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.
Gupta S; Solomon JM; Tasciyan TA; Cao MM; Stone RD; Ostuni JL; Ohayon JM; Muraro PA; Frank JA; Richert ND; McFarland HF; Bagnato F
Mult Scler; 2005 Dec; 11(6):658-68. PubMed ID: 16320725
[TBL] [Abstract][Full Text] [Related]
16. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
17. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
18. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
Bagnato F; Gupta S; Richert ND; Stone RD; Ohayon JM; Frank JA; McFarland HF
Arch Neurol; 2005 Nov; 62(11):1684-8. PubMed ID: 16157739
[TBL] [Abstract][Full Text] [Related]
19. An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis.
Di Rezze S; Gupta S; Durastanti V; Millefiorini E; Pozzilli C; Bagnato F
Mult Scler; 2007 Apr; 13(3):343-7. PubMed ID: 17439903
[TBL] [Abstract][Full Text] [Related]
20. Power analyses for negative binomial models with application to multiple sclerosis clinical trials.
Rettiganti M; Nagaraja HN
J Biopharm Stat; 2012; 22(2):237-59. PubMed ID: 22251172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
